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SHORT COMMUNICATION
Correlation between chromosome 5q deletions and different mechanisms
of c-myc overexpression in human colorectal cancer
R. Maestro, A. Viel & M. Boiocchi
Division ofExperimental Oncology I, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy.
c-myc is a nuclear proto-oncogene coding for a protein which
acts as a necessary, but not sufficient factor in the signal
pathway that allows a cell to progress throughout the cell
cycle (Campisi et al., 1984; Hann et al., 1985; Leder et al.,
1986; Womer et al., 1987). Its overexpression may play an
important role in neoplastic transformation (Astrin & Cos-
tanzi, 1989). c-myc mRNA is, in fact, frequently overexpress-
ed in colorectal tumours, but the causes of this phenomenon,
which do not reside in structural modifications of the locus
(Erisman et al., 1985; Viel et al., 1990), are at present not
known. The identification of the molecular bases of such an
overexpression, therefore, constitutes a topic of major
interest.
A gene with a possible regulatory function with respect to
c-myc expression has recently been hypothesised to map on
chromosome 5. The functional loss, either by mutation or
deletion, of this gene would allow the c-myc gene an uncon-
trolled transcriptional activity. This hypothesis follows from
the observation that colorectal carcinomas which overexpress
c-myc gene frequently display deletions of the long arm of
chromosome 5 (Erisman et al., 1989).
As previously demonstrated, however, two independent
phenomena accounting for c-myc mRNA overexpression can
occur separately or concomitantly in colorectal cancer. The
first one is an 'apparent' c-myc overexpression, being sub-
stantially consequent to an increase in cell growth rate of the
neoplastic tissue. Since c-myc expression is strictly associated
with cellular proliferation, for every augmentation in cycling
cell number of a tissue there is a proportional increase in
c-myc mRNA level, in a context ofunaltered c-myc transcrip-
tional control mechanisms. This phenomenon occurs in
about 70% of tumours. The second phenomenon is a real
transcriptional deregulation of the c-myc gene where c-myc
overexpression entity cannot be accounted for by a propor-
tional augmentation in cell growth rate. This phenomenon,
which can occur concomitantly with the first one, involves a
subset comprising about 50% of the tumours (Table I) (Viel
et al., 1990).
On these grounds, we asked whether one of the two phe-
nomona responsible for c-myc overexpression might signi-
ficantly correlate with chromosome 5q deletions in colorectal
cancers. DNA samples of Tumour/Normal tissue pairs from
22 colorectal cancer patients, heterozygous for the AMS8
probe, which maps on 5q34-qter region (Solomon et al.,
1987), were tested for Sq deletions by Southern blot analysis.
Among them, four cases of Sq allelic loss were detected
(C220, C229, C230, C244) (Figure 1), with a frequency (18%)
in agreement with most previous reports (Solomon et al.,
1987; Rees et al., 1989; Ashton-Rickardt et al., 1989). The
four tumours with 5q allelic deletion showed an increase in
cell growth rate and a consequent 'apparent' c-myc over-
expression, but only two of them (C220, C230) displayed a
'real' transcriptional deregulation of the gene (Table I). The
loss of 5q was, therefore, equally distributed among 'real'
and 'apparent' c-myc overexpressing tumours.
The finding of chromosome 5 deletions in physiologically
c-myc regulated tumours (C299, C244) seems to rule out a
direct relationship between 5q deletion and c-myc gene trans-
criptional deregulation. On the other hand, 5q allelic dele-
tions might be related to the increased cell growth rate of
neoplastic tissue. The gene responsible for the Familial
Adenomatous Polyposis (FAP) is located on chromosome 5
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ac-mycoverexpressionentitywasestimated astheratiobetweenc-myc
mRNA level in tumour and corresponding normal colorectal mucosa.
Two independent phenomena can account for the enhanced c-myc
mRNA expression observed in neoplastic tissue: (1) increased cellular
proliferation rate (see column b), (2) c-myc gene transcriptional
deregulation (see columnc) (Viel et al., 1990). b Cellular hyperprolifera-
tion entity of the neoplastic tissue was estimated as the ratio between
proliferative activity ofthe tumoural cell population relative to that of
the corresponding normal one. This parameter has been evaluated on
the basis of the S-phase specific histone H3 mRNA expression, which
provides a good estimate ofcell growth fraction (Baserga, 1981). The
ratio is indicative of the c-myc overexpression rate consequent to
increases in cell growth fraction ofneoplastic tissue. 'c-myc transcrip-
tional deregulation rate of neoplastic tissue has been calculated as the
ratio between c-myc mRNA overexpression (a) and cellular hyperpro-
liferation entity (b). The ratio represents the c-myc overexpression rate
notaccounted forbyincreasesincellgrowth fractionoftumoural tissue.
Dash indicates c-myctranscriptional deregulation rates <2. *Tumours
with chromosome 5q deletion. Methods: Total cellular RNA was
extracted from neoplastic and normal tissues by the guanidine chloride
method (Cox, 1968). c-myc and histone H3 mRNA expression levels
were determined by densitometric scanning ofboth Northern and Dot
blots, performed as described (Viel et al., 1990).
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Figure 1 Loss of heterozygosity ofchromosome 5 in informative
colorectal tumours. DNA from matched tumour (T) and normal
(N) pairs hybridised with AMS8 minisatellite probe, mapping on
5q34-qter region (Solomon et al., 1987). Although allele loss is
presumed to be complete in the tumour cells, being an early event
(Vogelstein et al., 1988), contamination of the sample with nor-
mal cells causes a reduction, rather than absolute loss of signal
for one allele (Solomon et al., 1987). In our cases, however, the
contamination was usually less than 30%. Patients' numbers refer
to Table I. C240 represents a control DNA. Methods: DNA
extracted from tumour biopsies (T) and normal adjacent mucosa
(N) was digested with Hinfl (New England Biolabs), electrophor-
esed on 0.8% agarose gels and blotted onto nylon membranes.
AMS8 probe was oligo-labelled with a32P dCTP. Hybridisation
and washing were by standard methods (Viel et al., 1990).
(Bodmer et al., 1987; Leppert et al., 1987), in the same arm
recognized by the AMS8 locus-specific hypervariable probe
(Wong et al., 1987). FAP is an autosomal dominant synd-
rome characterised by the development of hundreds of colo-
rectal polyps that lead to the occurrence of frank carcinoma
as early as 40 years of age (Bussey, 1975). Even if not yet
isolated, the FAP gene product appears to act as a negative
regulator of colonic epithelial proliferation. The inheritance
of a mutated FAP allele seems, in fact, sufficient to induce a
typical preneoplastic syndrome characterised by widespread
hyperproliferation of the colonic tissue and consequent
development of adenomas. The transition from adenoma to
carcinoma may follow the functional loss of the other FAP
allele (Bodmer et al., 1987) or, more likely, other genetic
changes such as deletions of chromosome 17, 18 or ras
mutations (Vogelstein et al., 1988). Similarly, also in the
sporadic form of colorectal cancer, the somatic loss of one
FAP allele might determine a promoting effect on cellular
proliferation. In agreement with this hypothesis, all four
tumours with 5q loss displayed an increased proliferative
activity and consequently an 'apparent' c-myc overexpres-
sion, as compared to corresponding normal mucosa. Con-
cerning the hyperproliferating carcinomas not displaying
AMS8 allelic deletion (Table I), the increase in cell growth
rate might be due to genetic alterations affecting FAP gene,
such as point mutations or interstitial deletions, not detec-
table by the experimental approach used.
In conclusion, our data do seem to indicate that chromo-
some 5q allelic deletion, by inducing a hyperproliferative
condition of the neoplastic tissue, may be responsible for the
genesis of an 'apparent' c-myc overexpression in human colo-
rectal tumours.
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